A clinical trial to study the effect of two drugs, Rasnadidashmool kwatha and Erandadi kwath in patients of Amavata (Rheumatoid Arthritis).

To evaluate upshayatmaka effect of Rasnadidashmool kwath in disintegration of etiopathogenesis of Amavata

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011537

Enrollment

100

Registered

2018-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of Amavata without any other co-existing disease

Interventions

Intervention1: Rasnadidashmool Kwath: 48gm BD in kwath form for 35 days Control Intervention1: Erandadi Kwath: 48gm BD in kwath form for 35 days

Eligibility

Inclusion criteria

Inclusion criteria: 1-Amavata of any dosha Anubandha 2-Diagnosis of Amavata as per symptoms described in Madhav Nidana 3-Diagnosis of Rheumatoid arthritis as per ACR criteria

Exclusion criteria

Exclusion criteria: 1-Pregnant women and lactating mother 2-Patients of RA with know case of rheumatic fever juvenile RA, Ankylosing spondylitis 3-Patients of RA with complications like deformity 4-Any other disorder with Amavata

Design outcomes

Primary

Measure	Time frame
Symptomatic relief in cardinal signs and symptoms of patients Improvement in DAS-28 ScoreTimepoint: 35 days	—

Secondary

Measure	Time frame
Subjective improvement in the patients will be assessed by adopting suitable scoring pattern. Decrease in elevated levels of CRP,ESR,RA factor and other biochemical parameters. Assessment of grip strength and walking time by suitable method.Timepoint: 35 days	—

Countries

India

Contacts

Public ContactDr Anant Kumar

Ch. Brahm Prakash Ayurveda Charak Sansthan

dr.aditaya@gmail.com9711434847

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026